Ruxolitinib
Active ingredient · 2 therapeutic classes
Sold as JAKAVI · OPZELURA
- Drug class
- Janus-Associated Kinase (Jak) Inhibitors
- Availability
- See label
- Routes
- Topical, Oral
- Markets covered
- 3
- Products on record
- 26
Overview
Ruxolitinib is an active pharmaceutical ingredient in the Janus-Associated Kinase (Jak) Inhibitors group (L01EJ). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 19 | May 29, 2026 |
| CA Canada | Health Canada | 5 | November 10, 2025 |
| EU European Union | EMA | 2 | March 23, 2026 |
GBUnited Kingdom· MHRA
19 products
Uses
Myelofibrosis (MF) Ruxolitinib is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.
Polycythaemia vera (PV) Ruxolitinib is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. 1). 1).
How to take
CACanada· Health Canada
5 products
Uses
3 Pediatrics 05/2022 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ...........................................................................................
2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................
4 1 INDICATIONS ................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................... 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX .................................................
5 4 DOSAGE AND ADMINISTRATION ...................................................................... 12 5 OVERDOSAGE ................................................................................................ 12 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING....................
EUEuropean Union· EMA
2 products
Uses
Opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
How to take
Drug interactions
Known interactions involving Ruxolitinib. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 287. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL508050113 · revised April 23, 2026
- [2]Health Canada (DPD) · 02388006 · revised May 12, 2025
- [3]European Medicines Agency · EMEA/H/C/005843 · revised March 23, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.